Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter Phase 2 Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Relapsed or Refractory Mantle Cell Lymphoma

NCT01236391 is registered in ClinicalTrials.gov with Pharmacyclics LLC. as lead sponsor.

NCT NCT01236391
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01236391 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter Phase 2 Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Relapsed or Refractory Mantle Cell Lymphoma
Lead sponsor
Pharmacyclics LLC.
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2011
Completion date
January 31, 2014
Enrollment
115 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

mantle cell lymphoma